SXTP

60 Degrees Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website 60degreespharma.com
Employees(FY) 2
ISIN US83006G2030

Performance

-5.26%

-15.89%

-52.88%

-73.13%

-92.65%

YTD

-86.75%

Profile

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is based in Washington, District Of Columbia.

Advanced Technical Analysis

Technical Analysis of SXTP 2024-11-22

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 16 indicating strong downward pressure, while the Oscillators Score of 56 suggests a neutral stance. Overall, the Technical Score of 36 reinforces the bearish outlook, signaling caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SXTP

Stock Rank

Recent News & Updates

2024-11-21 20:00
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV(Accesswire)
2024-11-14 01:31
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results(Globenewswire)
2024-10-02 21:02
60 Degrees Pharmaceuticals Inc. Announces ARAKODA Promotional Pilot in Advance of Expanded U.S. Launch(Globenewswire)
2024-09-05 20:59
60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules(Globenewswire)
2024-09-03 20:00
60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules(Globenewswire)
2024-08-28 02:48
60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements(Globenewswire)
2024-08-13 23:01
60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results(Globenewswire)
2024-08-11 21:12
60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA NDA in Support of SJ733 Phase IIb Study(Globenewswire)
2024-08-05 21:26
60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split(Globenewswire)
2024-07-24 21:02
60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA Supply Chain Upgrade Support(Globenewswire)
2024-07-18 20:29
60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study(Globenewswire)
2024-07-08 19:39
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday(Investorplace)
2024-07-08 18:31
60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment(Globenewswire)
2024-06-26 19:59
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind(Globenewswire)
2024-06-10 19:59
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis(Globenewswire)
2024-06-05 19:38
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday(Investorplace)
2024-05-29 19:59
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind(Globenewswire)
2024-05-19 19:59
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study(Globenewswire)
2024-05-15 09:55
SXTP Stock Earnings: 60 Degrees Reported Results for Q1 2024(Investorplace)
2024-05-15 01:45
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results(Globenewswire)
2024-05-07 19:59
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases(Globenewswire)
2024-05-01 19:59
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required(Globenewswire)
2024-04-02 19:58
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis(Globenewswire)
2024-03-13 19:59
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024(Globenewswire)
2024-02-19 18:59
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris(Globenewswire)
2024-02-07 18:59
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer(Globenewswire)
2024-01-30 23:00
WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering(Prnewswire)
2024-01-30 22:15
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering(Globenewswire)
2024-01-29 20:45
WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering(Prnewswire)
2024-01-29 20:00
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering(Globenewswire)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.